Rigollet Jaime Pablo Kelly, Ondategui Joan Anton, Pasto Angels, Lop Laura
Institut Català de la Salut, Centre de Atenció Primària MANSO, Eixample esquerra, Barcelona, Spain.
Clin Ophthalmol. 2011;5:187-91. doi: 10.2147/OPTH.S16666. Epub 2011 Feb 10.
To evaluate the long-term efficacy and safety of 3 commercially available fixed combinations of prostaglandin analogs or a prostamide with timolol maleate in patients with primary open angle glaucoma or ocular hypertension.
In this randomized, prospective, single-blind study, intraocular pressure (IOP) was measured after a 1-month washout period and pachymetry was performed before randomizing patients to latanoprost 50 μg/timolol 5 mg/1 mL (L/T), bimatoprost 300 μg/timolol 5 mg/1 mL (B/T), or travoprost 40 μg/timolol 5 mg/1 mL (T/T). IOP was measured monthly for 6 months and then at 12 months by an investigator blinded to the study drug. Adverse reactions were recorded.
128 cases were included in the study. The 3 treatment groups had similar baseline characteristics and comparable IOP. All 3 combinations decreased IOP by at least 6 mmHg and IOP remained below 21 mmHg throughout the study. At 12 months L/T achieved greater reduction in IOP than the other 2 fixed combinations, but the difference between L/T and B/T was not statistically significant. At 6 months, more B/T-treated patients reported red eye (P < 0.05 vs L/T and T/T). At 12 months, fewer adverse reactions were reported, with no cases of red eye reported for L/T (P = 0.03 vs B/T).
All 3 combinations are effective at lowering IOP but at 12 months L/T and B/T were found to be more effective than T/T. Treatments were well tolerated after 12 months but L/T showed less hyperemia than B/T throughout the study (P < 0.05).
评估三种市售的前列腺素类似物或前列腺酰胺与马来酸噻吗洛尔的固定组合在原发性开角型青光眼或高眼压症患者中的长期疗效和安全性。
在这项随机、前瞻性、单盲研究中,在1个月的洗脱期后测量眼压,并在将患者随机分为拉坦前列素50μg/噻吗洛尔5mg/1mL(L/T)、比马前列素300μg/噻吗洛尔5mg/1mL(B/T)或曲伏前列素40μg/噻吗洛尔5mg/1mL(T/T)之前进行角膜测厚。由对研究药物不知情的研究者每月测量眼压,持续6个月,然后在12个月时测量。记录不良反应。
128例患者纳入研究。三个治疗组的基线特征相似,眼压相当。所有三种组合均使眼压降低至少6mmHg,并且在整个研究过程中眼压均保持在21mmHg以下。在12个月时,L/T组眼压降低幅度大于其他两种固定组合,但L/T组与B/T组之间的差异无统计学意义。在6个月时,接受B/T治疗的患者中更多人报告有眼红症状(与L/T组和T/T组相比,P<0.05)。在12个月时,报告的不良反应较少,L/T组未报告有眼红病例(与B/T组相比,P=0.03)。
所有三种组合在降低眼压方面均有效,但在12个月时发现L/T组和B/T组比T/T组更有效。12个月后治疗耐受性良好,但在整个研究过程中L/T组的充血症状比B/T组少(P<0.05)。